These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8951694)

  • 1. Determination of plasma concentrations of SCH 44643 by a GC method and correlation of plasma concentration and anti-PAF activity in cynomolgus monkeys.
    Lin CC; Billah M; Kim HK; Egan R; Anthes J; Gilchrest H; Cayen M
    J Pharm Biomed Anal; 1996 Dec; 15(3):343-7. PubMed ID: 8951694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine.
    Billah MM; Chapman RW; Egan RW; Gilchrest H; Piwinski JJ; Sherwood J; Siegel MI; West RE; Kreutner W
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1090-6. PubMed ID: 2319461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans.
    Billah MM; Gilchrest HG; Eckel SP; Granzow CA; Lawton PJ; Radwanski E; Brannan MD; Affrime MB; Christopher JD; Richards W
    Clin Pharmacol Ther; 1992 Aug; 52(2):151-9. PubMed ID: 1505150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor (Paf) antagonist, WEB 2086, protects against Paf-induced hypotension in Macaca fascicularis.
    Stanton AW; Izumi T; Antoniw JW; Piper PJ
    Br J Pharmacol; 1989 Jul; 97(3):643-6. PubMed ID: 2758235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration.
    Lin C; Gupta S; Loebenberg D; Cayen MN
    Antimicrob Agents Chemother; 2000 Apr; 44(4):916-9. PubMed ID: 10722491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers.
    Pinquier JL; Sedivy P; Bruno R; Bompart F; Gregoire J; Strauch G; Gaillot J; Clucas A
    Eur J Clin Pharmacol; 1991; 41(2):141-5. PubMed ID: 1743246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM; Laplace MC; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-activating factor (PAF) stimulates the lysoPAF acetyltransferase in leukocyte-rich plasma: use in PAF antagonist studies.
    Doebber TW; Wu MS; Mauriello A; Alberts A
    Lipids; 1991 Dec; 26(12):997-1003. PubMed ID: 1819756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the active antifungal enantiomer, SCH 42427 (RR), and evaluation of its chiral inversion in animals following its oral administration and the oral administration of its racemate genaconazole (RR/SS).
    Kim H; Radwanski E; Lovey R; Lin CC; Nomeir AA
    Chirality; 2002 May; 14(5):436-41. PubMed ID: 11984759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
    Carceller E; Almansa C; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1992 Oct; 35(22):4118-34. PubMed ID: 1433215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man.
    Hayes JP; Ridge SM; Griffith S; Barnes PJ; Chung KF
    J Allergy Clin Immunol; 1991 Jul; 88(1):83-8. PubMed ID: 2071787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals.
    Kusano K; Tadano K; Tanaka S; Kagei Y; Ueda M; Miyazawa S; Abe Y; Ida S; Yuzuriha T
    Biol Pharm Bull; 1994 Feb; 17(2):334-9. PubMed ID: 8205134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic injury.
    Kelly KJ; Tolkoff-Rubin NE; Rubin RH; Williams WW; Meehan SM; Meschter CL; Christenson JG; Bonventre JV
    Am J Physiol; 1996 Nov; 271(5 Pt 2):F1061-7. PubMed ID: 8946001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-activating factor (PAF) in allergic diseases: inhibitory effects of anti-allergic drugs, ketotifen and three kampo medicines on PAF production.
    Nakamura T; Kuriyama M; Ishihara K; Matsumura Y; Miyamoto T
    Lipids; 1991 Dec; 26(12):1297-300. PubMed ID: 1726443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of platelet activating factor antagonists from Phoma sp.
    Chu M; Truumees I; Gunnarsson I; Bishop WR; Kreutner W; Horan AC; Patel MG; Gullo VP; Puar MS
    J Antibiot (Tokyo); 1993 Apr; 46(4):554-63. PubMed ID: 8500998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.